HDFN remains a challenge for immunohematology laboratories. Identifying women at risk of developing anti-D and indicating the proper prophylaxis with anti-D immunoglobulin is an important step towards preventing HDFN by reducing the rate of alloimmunization of anti-D. Once alloimmunization anti-D is detected in a pregnant woman, it is key to verify anti-D levels by antibody titration and to monitor for fetal anemia. These steps are vital to ensure positive pregnancy outcomes.
Other antibody specificities besides anti-D may cause HDFN. What steps must be taken to ensure good outcomes for these specificities? In addition, what steps should be taken to care for mothers presenting with partial RhD?
In this webinar, Carla Dinardo, MD, PhD, will give us an overview of the physiopathology of this complex disease. Dr. Dinardo will additionally tell us how HDFN can be prevented, or diagnosed and treated.
Carla Dinardo
MD, PhD
Carla Dinardo is the director at Fundação Pró-Sangue Hemocentro de São Paulo and leads the Immunohematology Division. She graduated in medicine in 2005, followed by a specialty in internal medicine (2006-2008) and in hematology and hemotherapy (2008-2010).
She began her career as a hematologist in 2012 and as head of the Immunohematology Division of Fundação Pró-Sangue Hemocentro de São Paulo. Since then, she has been involved in multiple projects involving blood group system genetics, red blood cell alloimmunization, and general transfusion practice. In the past four years, she has acted as a researcher for the National Heart, Lung, and Blood Institute’s Recipient Epidemiology and Donor Evaluation Study III in Brazil, in collaboration with the Vitalant Research Institute in San Francisco. Since 2020, she has been a director of External Relations at the Fundação Pró-Sangue and member of the Young Professional Council of the International Society of Blood Transfusion, representing Latin America.